Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference

BRISBANE, Calif.--(BUSINESS WIRE)--Apr. 3, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Jayson Dallas, M.D., President and Chief Executive Officer, will present at the Needham & Company 18th Annual Healthcare Conference on Wednesday, April 10, 2019, at 8:00 a.m. Eastern Time in New York City.

A live webcast of the presentation will be accessible on the Events page under the Investor Relations section of the Aimmune website at www.aimmune.com. A replay will also be available following the webcast.

About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company developing oral treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to provide meaningful levels of protection against allergic reactions resulting from accidental exposure to food allergens by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product, AR101, is being developed as a treatment to reduce the risk of anaphylaxis following accidental exposures to peanut. The BLA for AR101 is under review by the FDA, which in 2015 granted AR101 Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4 to 17 years of age. Aimmune expects to file for marketing approval of AR101 in Europe in mid-2019. Aimmune has filed an IND application for its second product, AR201 for the treatment of egg allergy, and intends to start a randomized phase 2 clinical trial in mid-2019. For more information, please see www.aimmune.com.

Source: Aimmune Therapeutics, Inc.

Investors:
Eric Bjerkholt
(650) 376-5582 or
ebjerkholt@aimmune.com

Media:
Alison Marquiss
(650) 376-5583 or
amarquiss@aimmune.com